Jerusalem, Israel

Abraham Loyter

This inventor holds 3 USPTO granted patents and 1 published patent application and 1 EPO patent. Top assignees: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd., Other. Active years: 2003-2017.

USPTO Granted Patents = 3 

% Patents Active = 100.0

 

Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2003-2017

Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: The Innovative Journey of Abraham Loyter

Introduction: Abraham Loyter, a pioneering inventor hailing from Jerusalem, Israel, has made significant contributions to the field of science and technology through his groundbreaking inventions.

Latest Patents: Abraham Loyter holds several patents in the areas of biotechnology and nanotechnology, with his most recent patent focusing on a novel method for enhancing drug delivery systems using nanomaterials.

Career Highlights: Throughout his illustrious career, Abraham Loyter has been recognized for his innovative spirit and dedication to pushing the boundaries of scientific discovery. His work has led to advancements in various fields, including healthcare, materials science, and environmental sustainability.

Collaborations: Abraham Loyter has collaborated with leading research institutions, universities, and biotechnology companies around the world to further develop and commercialize his inventions. His collaborative efforts have resulted in the successful implementation of cutting-edge technologies in real-world applications.

Conclusion: In conclusion, Abraham Loyter's relentless pursuit of innovation and his passion for creating solutions to complex challenges have solidified his reputation as a visionary inventor. His contributions continue to inspire the next generation of inventors and pave the way for a brighter future in the world of science and technology.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…